{"nctId":"NCT04327843","briefTitle":"Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)","startDateStruct":{"date":"2019-11-05","type":"ACTUAL"},"conditions":["Schizophrenia","Medication Nonadherence","Schizo Affective Disorder"],"count":22,"armGroups":[{"label":"CAE + LAI","type":"EXPERIMENTAL","interventionNames":["Behavioral: Customized Adherence Enhancement","Drug: Haloperidol Decanoate"]}],"interventions":[{"name":"Customized Adherence Enhancement","otherNames":["CAE"]},{"name":"Haloperidol Decanoate","otherNames":["Haldol Decanoate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 and older\n* Diagnosis of schizophrenia or schizoaffective disorder\n* Known to have medication treatment adherence problems as identified by the TRQ (20% or more missed medications in past week or past month)\n* Ability to be rated on psychiatric rating scales\n* Willingness to take long-acting injectable medication\n* Able to provide written, informed consent to study participation\n\nExclusion Criteria:\n\n* History of allergy or intolerance to haloperidol or haloperidol decanoate\n* Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment\n* Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial\n* Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist\n* Immediate risk of harm to self or others\n* Female who is currently pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tablets Routine Questionnaire (TRQ)","description":"The TRQ evaluates adherence to medications via a brief self-report instrument that has been validated in populations with bipolar disorder medication adherence. The TRQ identifies nonadherent individuals, defined as those who miss 20-30% or more of their medication in the last week or month. Total scores are represented as a percentage and range from 0 to 100, with higher scores indicating a greater level of nonadherence (higher scores indicate worse adherence to medications).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57","spread":"60.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Long-Acting Injectable Adherence (LAI Adherence): Count of Participants Who Received All LAI Injections:","description":"LAI injection adherence will be determined as a count of participants who received LAI injections at the appropriate time (within 7 days of scheduled time).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Drug Attitude Inventory (DAI)","description":"DAI-10 scoring ranges from -10 to +10 with a total score \\>0 indicating a positive attitude toward psychiatric medications and a total score of \\<0 indicating a negative attitude toward psychiatric medications.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.89","spread":"2.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.83","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Brief Psychiatric Rating Scale (BPRS)","description":"The BPRS measures levels of mania. There are 24 items, scored on a 7-point scale ranging from 0 to 6. Total scores range from 0 to 42, with higher scores indicating higher levels of mania.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.00","spread":"10.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.06","spread":"8.53"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions (CGI)","description":"The minimum possible score is 1 and the maximum score is 7. A higher score implies a worse condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Social and Occupational Functioning Scale (SOFAS)","description":"The SOFAS measures social and occupational functioning independent of the overall severity of the individual's psychological symptoms. The minimum score is 0 and the maximum score is 100. A higher rating implies a higher level of functioning.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.17","spread":"18.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.39","spread":"15.28"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index","description":"Body Mass Index kg/m\\^2 of participants","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.79","spread":"5.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.92","spread":"5.58"}]}]}]},{"type":"SECONDARY","title":"ESRS-A Parkinsonism","description":"Extrapyramidal Symptoms Scale-Abbreviated version for Parkinsonism. It looks at drug-induced Parkinsonism which is made up of motor disturbances. Rigidity, tremor, reduced facial expression/speech, impaired gait/posture, postural instability, and bradykinesia. Each item is rated on a 4 point scale: 0=absent, 3=severe. The higher the value the more severe the Parkinsonism and worst outcomes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"ESRS-A Dystonia","description":"Extrapyramidal Symptoms Scale-Abbreviated version for dystonia- drug-induced dystonia is a muscle disorder in which movements are jerky or twisting. Due to the 0.00 values at baseline and 25 weeks, unable to perform t-test and get a p value so no statistical analysis section is reported for this Outcome Measure. Each item is rated on a 4 point scale: 0=absent, 3=severe with the higher numbers indicating worse dystonia and worse outcomes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"ESRS-A Dyskinesia","description":"Extrapyramidal Symptoms Scale-Abbreviated version for Dyskinesia- drug-induced dyskinesia which is repetitive and involuntary movements. Each item is rated on a 4 point scale: 0=absent, 3=severe and higher values indicate greater severity of dyskinesia and worse outcomes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.47"}]}]}]},{"type":"SECONDARY","title":"ESRS-A Akathisia","description":"Extrapyramidal Symptoms Scale-Abbreviated version for akathisia- drug-induced akathisia consists of inner restlessness and urge to move. Items are measured on a 4 value scale: 0=absent, 3=severe, and higher values indicate more severe akathisia and worse outcomes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":19},"commonTop":["Tremor","Drowsiness","Blurry vision","Restlessness","Muscle pain"]}}}